Barely Significant
← all excerpts

An open-label, nonrandomized, phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinoma.

Clin Transl Sci · 2021 · PMC8604223 · PMID 34405542

1
hedged sentence
closest p
boldest claim

The sentences

borderline significantno p-value reported
In addition, EBV DNA copy numbers were positively correlated to sCD27 in serum at baseline in patients with measurable EBV DNA copy number (borderline significant), which might be attributed to the fact that an EBV infection triggers CD70 expression which, in turn, increases activity of CD27‐CD70 axis. 8 Interestingly, this correlation was absent following the first two administrations of cusatuzumab.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.